EODData

MEMBERSHIP REGISTER LOG IN

FRA, 52U: HYLORIS PHARMA. S.A.

19 Dec 2025
LAST:

6.100

CHANGE:
 0.22		OPEN:
5.800		HIGH:
6.100		ASK:
0.000		VOLUME:
5
CHG(%):
3.74		PREV:
5.880		LOW:
5.800		BID:
0.000		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
19 Dec 255.8006.1005.8006.1005
18 Dec 255.8805.8805.8805.880581
17 Dec 255.9405.9405.9405.940581
16 Dec 255.7805.7805.7805.780581
15 Dec 255.7805.7805.7805.780581
12 Dec 255.7405.7405.7405.740581
11 Dec 255.8405.8405.8405.840581
10 Dec 255.8405.8405.8405.840581
09 Dec 255.7805.7805.7805.780581
08 Dec 255.8405.8405.8405.840581

PROFILE

Name:HYLORIS PHARMA. S.A.
About:Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortality associated with an emergency cardiac event, such as myocardial infarction or stroke; Milrinone ER for right heart failure due to left ventricular device; Dofetilide IV to treat atrial fibrillation; Metolazone IV for the treatment of salt and water retention, including edema accompanying congestive heart failure and renal diseases; and HY-075 IV to prevent and treat cardiovascular diseases. The company offers other value-added products comprising Tranexamic Acid Oral Rinse for preventing and treating excessive bleeding in patients on blood thinners undergoing dental procedures; Alenura to treat pain associated with interstitial cystitis/bladder pain syndrome; Miconazole/Domiphen Bromide cream to treat vaginal infections caused by candida yeast and/or bacteria, including a biofilm; PTX-252 to treat acute myeloid leukemia; Atomoxetine oral Liquid for the treatment of attention deficit hyperactivity disorder; HY-083 to treat idiopathic rhinitis; HY-088 for hypophosphatemia; HY-090 to treat burning mouth syndrome; HY-091 for vulvar lichen sclerosis; HY-095 to treat equine gastric ulcer; Pantoprazole IV to treat gastric acidity, and ulcers and erosive esophagitis; Ondansetron for nausea and vomiting; and HY-094 to treat iron deficiency. It has collaboration agreement with FHP BV, Pleco Therapeutics, Vaneltix Pharma, Inc., and AFT Pharmaceuticals. The company was incorporated in 2012 and is headquartered in Liège, Belgium.
Sector:Healthcare
Industry:Biotechnology
Address:Boulevard Patience et Beaujonc N°3/1, Liège, Belgium, 4000
Website:https://hyloris.com
ISIN:BE0974363955
LEI:875500LZIWS7QEQE0I73

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:-24.17 
Price to Sales:20.14 
Price to Book:5.61 
Profit Margin:-0.76 
Operating Margin:-1.06 
Return on Assets:-0.09 
Return on Equity:-0.20 
Revenue:8.46M 
Shares:28.0M 
Market Cap:170.8M 

TECHNICAL INDICATORS

MA5:5.903.5%
MA10:5.854.2%
MA20:5.873.9%
MA50:5.716.7%
MA100:5.972.1%
MA200:5.962.4%
STO9:100.00 
STO14:100.00 
RSI14:55.00
MTM14:0.34
ROC14:0.06 
ATR:0.09 
Week High:6.100.0%
Week Low:5.746.3%
Month High:6.242.3%
Month Low:5.602.4%
Year High:7.1917.9%
Year Low:4.5434.5%
Volatility:63.00